Now Reading
Gene therapy can reduce risk of hemophilic bleeding
Subscribe
Sign In

Gene therapy can reduce risk of hemophilic bleeding

Hemophilia B typically needs repeat therapy. A one-time novel gene therapy could reduce bleeding.

Where: United Kingdom

The Facts

Results from a Phase 1-2 trial indicate that a one-time novel gene therapy can reduce the risk of excessive bleeding in hemophilia B.
The trial was funded by Freeline Therapeutics.
The results have been reported in the New England Journal of Medicine.
Lead author Prof. Pratima Chowdary stated, “Removing the need for haemophilia patients to regularly inject themselves with the missing protein is an important step in improving their quality of life.”
The long-term follow-up study will include surveillance for late effects.

Primary Sources

Direct, authoritative source material on this story.

Reference Articles

Articles Citable has ingested related to this story.

Reference Articles

Articles Citable has ingested related to this story.

Media Coverage

Why did we include this story

Most covered story by the media today

of articles referenced this story

Coverage by Media Outlet

Media outlets covering this story along with their positive or negative sentiment toward this story.

© 2021 Citable. All Rights Reserved.